Rituxan (Genentech, Inc.)
Welcome to the PulseAid listing for the Rituxan drug offered from Genentech, Inc.. This CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Genentech, Inc. |
| NON-PROPRIETARY NAME: | rituximab |
| SUBSTANCE NAME: | RITUXIMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 1997-11-26 |
| END MARKETING DATE: | 0000-00-00 |
Rituxan HUMAN PRESCRIPTION DRUG Details:
| Item Description | Rituxan from Genentech, Inc. |
| LABELER NAME: | Genentech, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 10(mg/mL) |
| START MARKETING DATE: | 1997-11-26 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50242-051_dbbf0d19-9518-4a12-a4e5-a5f77b005315 |
| PRODUCT NDC: | 50242-051 |
| APPLICATION NUMBER: | BLA103705 |
Other RITUXIMAB Pharmaceutical Manufacturers / Labelers:
